|
KR101483215B1
(ko)
*
|
2010-01-29 |
2015-01-16 |
한미약품 주식회사 |
단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
|
|
BR112013000868A2
(pt)
|
2010-07-13 |
2016-05-17 |
Hoffmann La Roche |
derivados de pirazol [1,5a] e tieno [3,2b] pirimidina como modulares de irak4
|
|
EP2663312B1
(en)
|
2011-01-10 |
2017-10-11 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP2688872A4
(en)
*
|
2011-03-22 |
2014-08-27 |
Merck Sharp & Dohme |
AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
|
|
EP2723746A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
WO2013100632A1
(en)
*
|
2011-12-30 |
2013-07-04 |
Hanmi Pharm Co., Ltd. |
THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
|
|
RU2637925C2
(ru)
|
2012-01-10 |
2017-12-08 |
Ф. Хоффманн-Ля Рош Аг |
Соединения тиенопиримидина
|
|
AU2013207972B2
(en)
*
|
2012-01-10 |
2017-06-15 |
Nimbus Iris, Inc. |
IRAK inhibitors and uses thereof
|
|
WO2014003483A1
(en)
*
|
2012-06-29 |
2014-01-03 |
Hanmi Pharm. Co., Ltd. |
Fused pyrimidine derivatives having inhibitory activity on fms kinases
|
|
US9216991B2
(en)
*
|
2012-07-10 |
2015-12-22 |
Ares Trading S.A. |
Pyrimidine pyrazolyl derivatives
|
|
JP2015528801A
(ja)
*
|
2012-07-11 |
2015-10-01 |
ニンバス アイリス， インコーポレイテッド |
Ｉｒａｋ阻害剤およびその使用
|
|
EP2872144A4
(en)
*
|
2012-07-11 |
2015-12-02 |
Nimbus Iris Inc |
IRAQ INHIBITOR AND USES THEREOF
|
|
WO2014011911A2
(en)
*
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
US9340546B2
(en)
|
2012-12-07 |
2016-05-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP2016505012A
(ja)
|
2013-01-10 |
2016-02-18 |
ニンバス アイリス， インコーポレイテッド |
Ｉｒａｋ阻害剤およびその使用
|
|
ES2649156T3
(es)
|
2013-01-14 |
2018-01-10 |
Incyte Holdings Corporation |
Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
|
|
US9200004B2
(en)
|
2013-01-15 |
2015-12-01 |
Incyte Holdings Corporation |
Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
|
|
US8778365B1
(en)
|
2013-01-31 |
2014-07-15 |
Merz Pharmaceuticals, Llc |
Topical compositions and methods for making and using same
|
|
WO2014143242A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
JP2016512239A
(ja)
|
2013-03-15 |
2016-04-25 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な化合物
|
|
US9663519B2
(en)
|
2013-03-15 |
2017-05-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
WO2015006181A1
(en)
|
2013-07-11 |
2015-01-15 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
|
PE20160532A1
(es)
*
|
2013-08-23 |
2016-05-21 |
Incyte Corp |
Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
|
|
CN106232122A
(zh)
|
2013-09-27 |
2016-12-14 |
林伯士艾瑞斯公司 |
Irak抑制剂和其用途
|
|
WO2015085132A1
(en)
|
2013-12-06 |
2015-06-11 |
Vertex Pharmaceuticals Incorporated |
2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
|
|
CA2932353A1
(en)
|
2013-12-13 |
2015-06-18 |
Steven P. Treon |
Methods to treat lymphoplasmacytic lymphoma
|
|
JP6879740B2
(ja)
|
2013-12-13 |
2021-06-02 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
リンパ形質細胞性リンパ腫を処置する方法
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
BR112016015983A2
(pt)
|
2014-01-10 |
2017-08-08 |
Aurigene Discovery Tech Ltd |
Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
|
|
CA2935887A1
(en)
|
2014-01-13 |
2015-07-16 |
Aurigene Discovery Technologies Limited |
Bicyclic heterocyclyl derivatives as irak4 inhibitors
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
PE20211782A1
(es)
|
2014-05-23 |
2021-09-08 |
Hoffmann La Roche |
Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
|
|
CN107074863B
(zh)
|
2014-06-05 |
2019-12-03 |
沃泰克斯药物股份有限公司 |
Atr激酶抑制剂的制备方法及其不同的固体形式
|
|
CA2950780C
(en)
|
2014-06-17 |
2023-05-16 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of chk1 and atr inhibitors
|
|
US9580418B2
(en)
|
2014-07-14 |
2017-02-28 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
US9822124B2
(en)
|
2014-07-14 |
2017-11-21 |
Incyte Corporation |
Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
JP6788583B2
(ja)
|
2014-10-22 |
2020-11-25 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
増殖性疾患を処置するためのチアゾリル含有化合物
|
|
WO2016073891A1
(en)
|
2014-11-06 |
2016-05-12 |
Lysosomal Therapeutics Inc. |
Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
|
|
SMT202400187T1
(it)
|
2014-11-06 |
2024-07-09 |
Bial R&D Investments S A |
Pirazolo(1,5-a)pirimidine sostituite e loro utilizzo nel trattamento di disturbi medici
|
|
ES2958391T3
(es)
|
2014-11-06 |
2024-02-08 |
Bial R&D Invest S A |
Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
|
|
LT3221306T
(lt)
*
|
2014-11-20 |
2020-03-10 |
Merck Patent Gmbh |
Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas
|
|
EP3268367B8
(en)
|
2015-03-12 |
2022-11-16 |
Merck Sharp & Dohme LLC |
Carboxamide inhibitors of irak4 activity
|
|
EP3267996B1
(en)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
|
US10040802B2
(en)
|
2015-03-12 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of IRAK4 activity
|
|
WO2016144848A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of irak4 activity
|
|
EP3268004B1
(en)
|
2015-03-12 |
2019-12-18 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of irak4 activity
|
|
WO2016196244A1
(en)
|
2015-05-29 |
2016-12-08 |
Incyte Corporation |
Pyridineamine compounds useful as pim kinase inhibitors
|
|
WO2017004134A1
(en)
*
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
KR20180025896A
(ko)
*
|
2015-07-15 |
2018-03-09 |
오리진 디스커버리 테크놀로지스 리미티드 |
Irak-4 저해제로서 인다졸 및 아자인다졸 화합물
|
|
AR105967A1
(es)
|
2015-09-09 |
2017-11-29 |
Incyte Corp |
Sales de un inhibidor de pim quinasa
|
|
CN113620833A
(zh)
|
2015-09-17 |
2021-11-09 |
希望之城 |
Pcna抑制剂
|
|
CN105237414B
(zh)
*
|
2015-09-30 |
2017-03-22 |
浙江永宁药业股份有限公司 |
ivacaftor中间体及其制备方法和用途
|
|
HK1258570A1
(zh)
|
2015-09-30 |
2019-11-15 |
Vertex Pharmaceuticals Inc. |
使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
|
|
WO2017059251A1
(en)
|
2015-10-02 |
2017-04-06 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
|
JP6895439B2
(ja)
*
|
2015-12-22 |
2021-06-30 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ＩＲＡＫ４調節因子としてのピラゾロ［１，５ａ］ピリミジン誘導体
|
|
SG11201808830YA
(en)
|
2016-04-06 |
2018-11-29 |
Lysosomal Therapeutics Inc |
Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
CA3020305A1
(en)
|
2016-04-06 |
2017-10-12 |
Lysosomal Therapeutics Inc. |
Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
EP3440081A4
(en)
|
2016-04-06 |
2019-09-18 |
Lysosomal Therapeutics Inc. |
PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
|
|
WO2017192841A1
(en)
*
|
2016-05-04 |
2017-11-09 |
Lysosomal Therapeutics Inc. |
Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
|
|
JP7164774B2
(ja)
|
2016-05-05 |
2022-11-02 |
ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ |
置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用
|
|
WO2017192931A1
(en)
|
2016-05-05 |
2017-11-09 |
Lysosomal Therapeutics Inc. |
SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
CN106222183B
(zh)
*
|
2016-07-25 |
2019-11-08 |
南通大学 |
靶向人irak1基因的小干扰rna及其应用
|
|
JP7059268B2
(ja)
|
2016-11-02 |
2022-04-25 |
エフ．ホフマン－ラ ロシュ アーゲー |
ＩＲＡＫ４モデュレーターとしてのピラゾロ［１，５ａ］ピリミジン誘導体
|
|
CA3052247A1
(en)
|
2017-02-01 |
2018-08-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors fortreating cancer
|
|
JOP20180011A1
(ar)
|
2017-02-16 |
2019-01-30 |
Gilead Sciences Inc |
مشتقات بيرولو [1، 2-b]بيريدازين
|
|
AU2018242623B2
(en)
|
2017-03-31 |
2024-05-02 |
Aurigene Oncology Limited |
Compounds and compositions for treating hematological disorders
|
|
CN106946890A
(zh)
*
|
2017-04-26 |
2017-07-14 |
中国药科大学 |
吡啶类irak4抑制剂、其制备方法及应用
|
|
EP3630766A1
(en)
|
2017-05-22 |
2020-04-08 |
H. Hoffnabb-La Roche Ag |
Therapeutic compounds and compositions, and methods of use thereof
|
|
CN111094292A
(zh)
*
|
2017-06-21 |
2020-05-01 |
豪夫迈·罗氏有限公司 |
作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
|
|
WO2018234343A1
(en)
*
|
2017-06-21 |
2018-12-27 |
F. Hoffmann-La Roche Ag |
Benzofurans as irak4 modulators
|
|
CN110785418A
(zh)
*
|
2017-06-21 |
2020-02-11 |
豪夫迈·罗氏有限公司 |
作为irak4调节剂的异二氢吲哚酮衍生物
|
|
WO2019001460A1
(zh)
*
|
2017-06-27 |
2019-01-03 |
南京明德新药研发股份有限公司 |
作为 irak4 抑制剂的稠环化合物
|
|
JP7114394B2
(ja)
*
|
2017-08-18 |
2022-08-08 |
住友化学株式会社 |
化合物、レジスト組成物及びレジストパターンの製造方法
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP4624467A2
(en)
|
2017-09-22 |
2025-10-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
AU2018359248B2
(en)
|
2017-10-31 |
2023-06-01 |
Curis, Inc. |
Compounds and compositions for treating hematological disorders
|
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
CN111542529B
(zh)
*
|
2017-11-30 |
2023-06-30 |
韩美药品株式会社 |
对蛋白激酶具有抑制活性的噻吩并[3,2-d]嘧啶化合物
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
JP7328987B6
(ja)
*
|
2018-04-05 |
2023-10-25 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｉｉ型ｉｒａｋ阻害剤としてのヘテロアリール化合物及びその使用
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
TWI721483B
(zh)
|
2018-07-13 |
2021-03-11 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
CN110862375B
(zh)
|
2018-08-27 |
2022-10-25 |
深圳铂立健医药有限公司 |
吡唑化合物及其药物组合物和应用
|
|
BR112021008176A2
(pt)
|
2018-10-30 |
2021-08-03 |
Kronos Bio, Inc. |
compostos, composições, e métodos para a modulação da atividade da cdk9.
|
|
KR102891608B1
(ko)
|
2018-11-30 |
2025-11-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
PE20220578A1
(es)
*
|
2019-06-27 |
2022-04-20 |
Biogen Ma Inc |
Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
|
|
WO2021066559A1
(en)
|
2019-10-02 |
2021-04-08 |
Kainos Medicine, Inc. |
N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
|
|
EP4076520A4
(en)
|
2019-12-17 |
2024-03-27 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US20230149407A1
(en)
|
2020-04-04 |
2023-05-18 |
Pfizer Inc. |
Methods of Treating Coronavirus Disease 2019
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
MX2023003698A
(es)
*
|
2020-09-30 |
2023-06-15 |
Asahi Kasei Pharma Corp |
Compuesto biciclico que contiene nitrogeno y pirimidina.
|
|
US11866405B2
(en)
|
2020-12-10 |
2024-01-09 |
Astrazeneca Ab |
Substituted indazoles as IRAK4 inhibitors
|
|
CN116867758A
(zh)
|
2020-12-30 |
2023-10-10 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
|
TW202245789A
(zh)
|
2021-02-15 |
2022-12-01 |
美商凱麥拉醫療公司 |
Irak4降解劑及其用途
|
|
MX2023009527A
(es)
|
2021-02-15 |
2023-08-24 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
JP2024516353A
(ja)
|
2021-04-08 |
2024-04-15 |
キュリス，インコーポレイテッド |
がんの治療のための併用療法
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
KR102869914B1
(ko)
*
|
2021-10-28 |
2025-10-13 |
재단법인 대구경북첨단의료산업진흥재단 |
신규한 티에노[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
|
|
IL312397A
(en)
|
2021-10-29 |
2024-06-01 |
Kymera Therapeutics Inc |
IRAK4 subunits and their synthesis
|
|
US12091411B2
(en)
|
2022-01-31 |
2024-09-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|